Iclusig यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

iclusig

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. pogledajte odjeljke 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

ZOLADEX LA 10.8mg Implant u napunjenom injekcionom špricu मोंटेनेग्रो - क्रोएशियाई - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

zoladex la 10.8mg implant u napunjenom injekcionom špricu

druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - goserelin - implant u napunjenom injekcionom špricu - 10.8mg

Tetavax, suspenzija za injekciju u napunjenoj štrcaljki, cjepivo protiv tetanusa, adsorbirano क्रोएशिया - क्रोएशियाई - HALMED (Agencija za lijekove i medicinske proizvode)

tetavax, suspenzija za injekciju u napunjenoj štrcaljki, cjepivo protiv tetanusa, adsorbirano

sanofi pasteur, 14 espace henry vallee, lyon, francuska - toksoid tetanusa - suspenzija za injekciju u napunjenoj štrcaljki - 1 doza = 0,5 ml - urbroj: jedna doza (0,5 ml) sadrži: toksoid tetanusa ≥ 40 iu adsorbiran na aluminijev hidroksid, hidrirani 0,6 mg al

Inrebic यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

inrebic

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastična sredstva - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Ytracis यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

ytracis

cis bio international - yttrium (90y) chloride - radionuklidno slikanje - dijagnostički radiofarmaceutici - upotrebljava se samo za radio-obilježavanje molekula nosača koji su posebno razvijeni i odobreni za radioaktivno obilježavanje s ovim radionuklidom. radiopharmaceutical precursor - not intended for direct application to patients.

Nebilet Plus 5 mg/12,5 mg filmom obložene tablete क्रोएशिया - क्रोएशियाई - HALMED (Agencija za lijekove i medicinske proizvode)

nebilet plus 5 mg/12,5 mg filmom obložene tablete

berlin-chemie menarini hrvatska d.o.o., horvatova 80a, zagreb, hrvatska - nebivololklorid hidroklorotiazid - filmom obložena tableta - 5 mg + 12,5 mg - urbroj: jedna tableta nebileta plus 5 mg / 12,5 mg sadrži 5 mg nebivolola (u obliku nebivololklorida: 2,5 mg srrr-nebivolola ili d-nebivolola i 2,5 mg rsss-nebivolola ili l-nebivolola) i 12,5 mg hidroklorotiazida

Nebilet Plus 5 mg/25 mg filmom obložene tablete क्रोएशिया - क्रोएशियाई - HALMED (Agencija za lijekove i medicinske proizvode)

nebilet plus 5 mg/25 mg filmom obložene tablete

berlin-chemie menarini hrvatska d.o.o., horvatova 80a, zagreb, hrvatska - nebivololklorid hidroklorotiazid - filmom obložena tableta - 5 mg + 25 mg - urbroj: jedna tableta nebileta plus 5 mg / 25 mg sadrži 5 mg nebivolola (u obliku nebivololklorida: 2,5 mg srrr-nebivolola ili d-nebivolola i 2,5 mg rsss-nebivolola ili l-nebivolola) i 25 mg hidroklorotiazida